GLP-1 Agonist Dosing Timeline: Semaglutide, Tirzepatide, Retatrutide

GLP-1 (glucagon-like peptide-1) is an incretin hormone released in the gut after eating. It signals fullness to the brain, slows stomach emptying, and improves insulin sensitivity. Pharmaceutical GLP-1 agonists mimic that signal for a week at a time instead of minutes.

Tirzepatide adds GIP receptor activation (dual agonist) and retatrutide adds glucagon receptors on top (triple agonist) — each added pathway increases average weight loss: roughly 15% for semaglutide, 21% for tirzepatide, and over 28% for retatrutide in their respective Phase 3/registration trials.

The problem: these hormones also drive nausea, vomiting, and delayed gastric emptying. Receptor sensitivity adapts over weeks — that is the entire basis of titration. Every escalation step in the schedules below exists to let the GI system and brain catch up before the next increase. Skipping steps does not speed results; it multiplies the side effects that make people quit.

Semaglutide (the active compound in Wegovy) is the most-studied GLP-1 agonist — 15% average weight loss at 68 weeks in the STEP clinical program, with long-term cardiovascular safety data. It is dosed once weekly with a ~7-day half-life.

Tirzepatide (the active compound in Zepbound) is a dual GIP/GLP-1 agonist with 20.9% average weight loss at 72 weeks in SURMOUNT-1 — the most effective FDA-approved single agent. Titration runs in 2.5 mg increments.

Because tirzepatide's GIP component improves lipid handling, its nausea profile is milder than semaglutide's at equivalent weight-loss effect — one reason it has become the first-line choice in many supervised protocols.

Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) with 28.3% average weight loss at 80 weeks in its Phase 3 program — the strongest result ever reported for a pharmaceutical weight-loss compound. It is not yet FDA-approved; everything below reflects research protocols.

Weeks 1–4 (adaptation phase)

Nausea is most likely in the 2–3 days after the first dose of any new step. Small, bland, low-fat meals; hydration with electrolytes; and not lying down after eating cover most of it. Acid reflux is common — take the shot on a consistent day and consider timing it in the evening.

Weeks 5–16 (escalation phase)

Each step-up briefly re-introduces days 1–2 intensity, then settles. Constipation replaces nausea as the top complaint as stomach emptying slows: fiber, fluids, and magnesium are the standard countermeasures. If you cannot eat adequate protein, hold the dose — muscle loss is the real risk during aggressive loss.

Red flags that mean stop and get evaluated

• •Severe, persistent abdominal pain (possible pancreatitis — this is an emergency)
• •Repeated vomiting preventing hydration
• •Signs of gallbladder problems: right-upper-abdominal pain after meals, especially fatty ones
• •Any allergic reaction: facial swelling, hives, difficulty breathing

A genuine plateau (4+ weeks with no change) is usually one of three things: adaptation (the current dose has done all it will), water retention masking fat loss, or intake creeping back up as portions quietly grow. The research answers, in order: hold the dose and reassess with trend data, verify protein and hydration, and only then consider one more step-up.

Breaks and cycling: GLP-1 research protocols typically run 16–24 week cycles followed by 4–8 weeks off. Receptor sensitivity partially recovers during breaks, and side effects fade. Weight regain during breaks is real but manageable with protein-forward eating and resistance training — plan the break, don't drift into it.